Poolbeg Pharma (LON:POLB) Earns House Stock Rating from Shore Capital

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reiterated by research analysts at Shore Capital in a research note issued on Thursday,London Stock Exchange reports.

Poolbeg Pharma Stock Down 1.6 %

POLB opened at GBX 4.20 ($0.05) on Thursday. The stock’s fifty day moving average is GBX 7.51 and its two-hundred day moving average is GBX 9.98. The company has a market capitalization of £21 million, a P/E ratio of -420.00 and a beta of 2.11. Poolbeg Pharma has a 52 week low of GBX 4.10 ($0.05) and a 52 week high of GBX 15.77 ($0.20).

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.